WO2024261733 - COMBINATIONAL TREATMENT
National phase entry:
Publication Number
WO/2024/261733
Publication Date
26.12.2024
International Application No.
PCT/IB2024/056106
International Filing Date
21.06.2024
Title **
[English]
COMBINATIONAL TREATMENT
[French]
POLYTHÉRAPIE
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 VALBY, DK
Inventors
RAZINKOV, Vladimir
c/o H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
BARNETT, Greg
c/o H. LUNDBECK A/S
Ottiliavej 9
Valby 2500, DK
ASUNI, Ayodeji Abdur-Rasheed
c/o H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
KROGH, Berit Olsen
c/o H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
KNELLER, Mark Byron
c/o H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Priority Data
63/509,854
23.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2218 | |
| EPO | Filing, Examination | 11077 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4960 |
Total: 19416 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a composition comprising Eptinezumab and LuAG09222. The composition can be used for treating or preventing e.g., headache, pain, migraine, cluster headache or endometriosis.[French]
La présente invention concerne une composition comprenant de l'eptinezumab et du LuAG09222. La composition peut être utilisée pour traiter ou prévenir, par exemple, une céphalée, une douleur, une migraine, une algie vasculaire de la face ou une endométriose.